Work

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

Year: 2011

Type: article

Study design: Clinical Trial

Source: Urology

DOI: 10.1016/j.urology.2011.04.041

Authors: William K. Oh, Matthew D. Galsky, Walter M. Stadler, Sandy Srinivas, Franklin Chu, Glenn Bubley, J. Goddard, Joi Dunbar, Robert W. Ross

Institutions: Icahn School of Medicine at Mount Sinai, University of Chicago, Stanford University, Beth Israel Deaconess Medical Center, Infinity Pharmaceuticals (United States), Dana-Farber Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: G3482955455

OpenAlex ID: W2082581177

FWCI: 6.948

Cites: 29

Cited by: 76

Related to: 10